{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:59:36Z","timestamp":1790056776895,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T00:00:00Z","timestamp":1488499200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00408-017-9990-8","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T18:02:10Z","timestamp":1488477730000},"page":"281-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study"],"prefix":"10.1007","volume":"195","author":[{"given":"Jaymin B.","family":"Morjaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Rigby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyn H.","family":"Morice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,3]]},"reference":[{"key":"9990_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD).(2014) Global strategy for the diagnosis, management and prevention of COPD, 2014. Available from: \nhttp:\/\/www.goldcopd.org\n\n. Accessed May 2016"},{"issue":"8","key":"9990_CR2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","volume":"356","author":"PM Calverley","year":"2007","unstructured":"Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356(8):775\u2013789","journal-title":"N Engl J Med"},{"issue":"509031936.00098","key":"9990_CR3","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1183\/09031936.00098307","volume":"31","author":"S Suissa","year":"2008","unstructured":"Suissa S, Ernst P, Vandemheen KL, Aaron SD (2008) Methodological issues in therapeutic trials of COPD. Eur Respir J 31(5):927\u2013933. doi: 09031936.00098307","journal-title":"Eur Respir J"},{"issue":"1","key":"9990_CR4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1183\/09031936.00190908","volume":"34","author":"S Suissa","year":"2009","unstructured":"Suissa S, Barnes PJ (2009) Inhaled corticosteroids in COPD: the case against. Eur Respir J 34(1):13\u201316","journal-title":"Eur Respir J"},{"issue":"1","key":"9990_CR5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1155\/2008\/173904","volume":"15","author":"J Bourbeau","year":"2008","unstructured":"Bourbeau J, Sebaldt RJ, Day A, Bouchard J, Kaplan A, Hernandez P, Rouleau M, Petrie A, Foster G, Thabane L, Haddon J, Scalera A (2008) Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J 15(1):13\u201319","journal-title":"Can Respir J"},{"issue":"23","key":"9990_CR6","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","volume":"374","author":"JA Wedzicha","year":"2016","unstructured":"Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF (2016) Indacaterol\u2013glycopyrronium versus Salmeterol\u2013fluticasone for COPD. N Engl J Med 374(23):2222\u20132234","journal-title":"N Engl J Med"},{"issue":"2","key":"9990_CR7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/bcp.12334","volume":"78","author":"KS Babu","year":"2014","unstructured":"Babu KS, Kastelik JA, Morjaria JB (2014) Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective. Br J Clin Pharmacol 78(2):282\u2013300","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"9990_CR8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-155-3-201108020-00008","volume":"155","author":"A Qaseem","year":"2011","unstructured":"Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schunemann H, Wedzicha W, MacDonald R, Shekelle P (2011) Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 155(3):179\u2013191","journal-title":"Ann Intern Med"},{"issue":"1","key":"9990_CR9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","volume":"177","author":"JA Wedzicha","year":"2008","unstructured":"Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA (2008) The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177(1):19\u201326","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"9990_CR10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1183\/09031936.00193908","volume":"34","author":"C Crim","year":"2009","unstructured":"Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J (2009) Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 34(3):641\u2013647","journal-title":"Eur Respir J"},{"issue":"3","key":"9990_CR11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1378\/chest.09-2992","volume":"139","author":"PM Calverley","year":"2011","unstructured":"Calverley PM, Stockley RA, Seemungal TA, Hagan G, Willits LR, Riley JH, Wedzicha JA (2011) Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 139(3):505\u2013512","journal-title":"Chest"},{"issue":"2","key":"9990_CR12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1164\/rccm.200602-244OC","volume":"175","author":"P Kardos","year":"2007","unstructured":"Kardos P, Wencker M, Glaab T, Vogelmeier C (2007) Impact of salmeterol\/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175(2):144\u2013149","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"9990_CR13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/15412550903140881","volume":"6","author":"A Anzueto","year":"2009","unstructured":"Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, Knobil K, O\u2019Dell D, Kalberg C, Crater G (2009) Effect of fluticasone propionate\/salmeterol (250\/50) on COPD exacerbations and impact on patient outcomes. COPD 6(5):320\u2013329","journal-title":"COPD"},{"issue":"3","key":"9990_CR14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/archinternmed.2008.550","volume":"169","author":"S Singh","year":"2009","unstructured":"Singh S, Amin AV, Loke YK (2009) Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 169(3):219\u2013229","journal-title":"Arch Intern Med"},{"issue":"20","key":"9990_CR15","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2008.717","volume":"300","author":"MB Drummond","year":"2008","unstructured":"Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E (2008) Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300(20):2407\u20132416","journal-title":"JAMA"},{"issue":"9691","key":"9990_CR16","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0140-6736(09)61250-2","volume":"374","author":"DD Sin","year":"2009","unstructured":"Sin DD, Tashkin D, Zhang X, Radner F, Sjobring U, Thoren A, Calverley PM, Rennard SI (2009) Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 374(9691):712\u2013719","journal-title":"Lancet"},{"issue":"7","key":"9990_CR17","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/j.1742-1241.2011.02685.x","volume":"65","author":"DM Halpin","year":"2011","unstructured":"Halpin DM, Gray J, Edwards SJ, Morais J, Singh D (2011) Budesonide\/formoterol vs. salmeterol\/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract 65(7):764\u2013774. doi:\n10.1111\/j.1742-1241.2011.02685.x","journal-title":"Int J Clin Pract"},{"issue":"11","key":"9990_CR18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/thoraxjnl-2012-202872","volume":"68","author":"S Suissa","year":"2013","unstructured":"Suissa S, Patenaude V, Lapi F, Ernst P (2013) Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 68(11):1029\u20131036","journal-title":"Thorax"},{"key":"9990_CR19","doi-asserted-by":"crossref","first-page":"f3306","DOI":"10.1136\/bmj.f3306","volume":"346","author":"C Janson","year":"2013","unstructured":"Janson C, Larsson K, Lisspers KH, Stallberg B, Stratelis G, Goike H, Jorgensen L, Johansson G (2013) Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ 346:f3306.","journal-title":"BMJ"},{"issue":"8","key":"9990_CR20","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.rmed.2014.05.013","volume":"108","author":"JA Wedzicha","year":"2014","unstructured":"Wedzicha JA, Singh D, Vestbo J, Paggiaro PL, Jones PW, Bonnet-Gonod F, Cohuet G, Corradi M, Vezzoli S, Petruzzelli S, Agusti A (2014) Extrafine beclomethasone\/formoterol in severe COPD patients with history of exacerbations. Respir Med 108(8):1153\u20131162","journal-title":"Respir Med"},{"issue":"2","key":"9990_CR21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.rmed.2011.07.020","volume":"106","author":"A Sharafkhaneh","year":"2012","unstructured":"Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ (2012) Effect of budesonide\/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 106(2):257\u2013268","journal-title":"Respir Med"},{"key":"9990_CR22","unstructured":"European Medicines Agency (2016) Review by the Committee for Medicinal Products for Human Use: Inhaled corticosteroids containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease. Published 18th March 2016. Accessed May 2016"},{"issue":"15","key":"9990_CR23","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","volume":"359","author":"DP Tashkin","year":"2008","unstructured":"Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359(15):1543\u20131554","journal-title":"N Engl J Med"},{"issue":"9318","key":"9990_CR24","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","volume":"359","author":"SJ Pocock","year":"2002","unstructured":"Pocock SJ, Clayton TC, Altman DG (2002) Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. The Lancet 359(9318):1686\u20131689","journal-title":"The Lancet"},{"key":"9990_CR25","unstructured":"CG101 Chronic obstructive pulmonary disease (update): full guideline [webpage on the Internet]. National Institute for Health and Clinical Excellence [updated May 30, 2012]. Available from: http:\/\/guidance. nice.org.uk\/CG101\/Guidance\/pdf\/English. Accessed Dec, 2014."},{"issue":"6","key":"9990_CR26","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/joim.12067","volume":"273","author":"K Larsson","year":"2013","unstructured":"Larsson K, Janson C, Lisspers K, Jorgensen L, Stratelis G, Telg G, Stallberg B, Johansson G (2013) Combination of budesonide\/formoterol more effective than fluticasone\/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Intern Med 273(6):584\u2013594","journal-title":"J Intern Med"},{"key":"9990_CR27","first-page":"1015","volume":"10","author":"N Zhong","year":"2015","unstructured":"Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D (2015) LANTERN: a randomized study of QVA149 versus salmeterol\/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis 10:1015\u20131026","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"9990_CR28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.iac.2005.05.004","volume":"25","author":"M Hubner","year":"2005","unstructured":"Hubner M, Hochhaus G, Derendorf H (2005) Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am 25(3):469\u2013488","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"9990_CR29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.0306-5251.2001.01493.x","volume":"52","author":"L Thorsson","year":"2001","unstructured":"Thorsson L, Edsbacker S, Kallen A, Lofdahl CG (2001) Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 52(5):529\u2013538","journal-title":"Br J Clin Pharmacol"},{"key":"9990_CR30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1465-9921-13-40","volume":"13","author":"CM Patterson","year":"2012","unstructured":"Patterson CM, Morrison RL, D\u2019Souza A, Teng XS, Happel KI (2012) Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniae in mice. Respir Res 13:40","journal-title":"Respir Res"},{"issue":"3","key":"9990_CR31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2213-2600(13)70040-7","volume":"1","author":"MT Dransfield","year":"2013","unstructured":"Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM (2013) Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 1(3):210\u2013223","journal-title":"Lancet Respir Med"},{"key":"9990_CR32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/COPD.S60498","volume":"9","author":"RL DiSantostefano","year":"2014","unstructured":"DiSantostefano RL, Li H, Hinds D, Galkin DV, Rubin DB (2014) Risk of pneumonia with inhaled corticosteroid\/long-acting beta2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis. Int J Chron Obstruct Pulmon Dis 9:457\u2013468","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"9990_CR33","doi-asserted-by":"crossref","unstructured":"Suissa S, Coulombe J, Ernst P (2015) Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia. Chest","DOI":"10.1378\/chest.15-0627"},{"issue":"14","key":"9990_CR34","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","volume":"371","author":"H Magnussen","year":"2014","unstructured":"Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EF, Calverley PM (2014) Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 371(14):1285\u20131294. doi:\n10.1056\/NEJMoa1407154","journal-title":"N Engl J Med"},{"issue":"9)","key":"9990_CR35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S2213-2600(15)00254-4","volume":"3","author":"ED Bateman","year":"2015","unstructured":"Bateman ED, Reddel HK, van Zyl-Smit RN, Agusti A (2015) The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med 3 (9):719\u2013728","journal-title":"Lancet Respir Med"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00408-017-9990-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-017-9990-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-017-9990-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T04:22:54Z","timestamp":1495081374000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00408-017-9990-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["9990"],"URL":"https:\/\/doi.org\/10.1007\/s00408-017-9990-8","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,3]]}}}